Firstly, semaglutide stimulates insulin secretion from pancreatic beta cells in a glucose-dependent mannermeaning it promotes insulin release only when blood glucose levels are elevated, thereby reducing the risk of hypoglycaemia
Unknown Pharmacokinetics We dont fully understand how these medications behave in the body at micro-doses, including their absorption, distribution, and elimination patterns
Discussion Despite several studies investigating the effects of combination therapy with GLP-1RA and SGLT2i in patients with T2D or obesity 21,22,23,24,25 , the present study is the first to focus on patients with MASLD and reveals several significant findings
While effective, they carry serious side effects and must be taken under specialist supervision